+44 20 8123 2220
info@marketpublishers.com

Lymphangioleiomyomatosis (LAM) - Pipeline Insight, 2020

https://marketpublishers.com/r/L6E60B52FBB3EN.html
Date: November 2020
Pages: 60
Price: US$ 1,500.00 (Single User License)
ID: L6E60B52FBB3EN

Abstracts

This report can be delivered to the clients within 24-48 Hours

DelveInsight's, "Lymphangioleiomyomatosis– Pipeline Insight, 2020," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Lymphangioleiomyomatosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Lymphangioleiomyomatosis Understanding

Lymphangioleiomyomatosis: Overview

Lymphangioleiomyomatosis (LAM) also known as lymphangiomyomatosis is a condition that affects the lungs, the kidneys, and the lymphatic system. The lymphatic system consists of a network of vessels that transport lymph fluid and immune cells throughout the body. Lymph fluid helps exchange immune cells, proteins, and other substances between the blood and tissues. LAM is found almost exclusively in women. It often occurs as a feature of an inherited syndrome called tuberous sclerosis complex. When LAM occurs alone it is called isolated or sporadic LAM.

+44 20 8123 2220
info@marketpublishers.com

Symptoms

Signs and symptoms of LAM most often appear during a woman's thirties. Affected women have an overgrowth of abnormal smooth muscle-like cells (LAM cells) in the lungs, resulting in the formation of lung cysts and the destruction of normal lung tissue. They may also have an accumulation of fluid in the cavity around the lungs (chylothorax). The lung abnormalities resulting from LAM may cause difficulty breathing (dyspnea), chest pain, and coughing, which may bring up blood (hemoptysis). Many women with this disorder have recurrent episodes of collapsed lung (spontaneous pneumothorax).

Diagnosis

Routine investigations can be supportive but not diagnostic in LAM. The chest radiograph often appears normal in early disease, although may show a pneumothorax or pleural effusion. The most common abnormalities are reticulonodular shadowing and cysts or bullae. The lung volumes are generally preserved and the combination of preserved lung volumes and interstitial changes occurs in a small number of conditions including LAM, Langerhans' cell histiocytosis, sarcoidosis and chronic hypersensitivity pneumonitis.

Treatment

Standard treatment of lymphangioleiomyomatosis is lung transplantation, but the disorder can recur in transplanted lungs. Rapamune (sirolimus) has been approved to treat lymphangioleiomyomatosis (LAM), a rare progressive lung disease that primarily affects women of childbearing age. Rapamune is manufactured by Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc. Treatment with sirolimus is recommended for patients with abnormal or declining lung function. Alternative treatments, such as hormonal manipulation with progestins, tamoxifen, and oophorectomy, are largely ineffective and not recommended.

Lymphangioleiomyomatosis Emerging Drugs Chapters

This segment of the Lymphangioleiomyomatosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

+44 20 8123 2220
info@marketpublishers.com

Lymphangioleiomyomatosis Emerging Drugs

Rapamycin- AI Therapeutics

LAM-001 is the world's first inhaled mTOR inhibitor and designed to treat the rare lung disease, lymphangioleiomyomatosis. LAM is a genetic-based disease found primarily in women and characterized by hyperactivation of mTOR signaling. LAM-001 has completed clinical trials in normal healthy volunteers and in patients with LAM disease.

Saracatinib: AstraZeneca

Saracatinib is a small molecule, highly-potent and selective inhibitor of src tyrosine kinase. The drug is currently in phase II stage of development for the treatment of LAM.

Further product details are provided in the report……..

Lymphangioleiomyomatosis: Therapeutic Assessment

This segment of the report provides insights about the different Lymphangioleiomyomatosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Lymphangioleiomyomatosis

There are approx. 10+ key companies which are developing the therapies for Lymphangioleiomyomatosis. The companies which have their Lymphangioleiomyomatosis drug candidates in the most advanced stage, i.e. phase II include, AI Therapeutics.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (BLA Filed and Phase III)

+44 20 8123 2220
info@marketpublishers.com

Mid-stage products (Phase II and

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Lymphangioleiomyomatosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intravenous

Intravesical

Oral etc.

Molecule Type

Products have been categorized under various Molecule types such as

Antineoplastics

Vaccine

Gene therapies

Immunotherapy

+44 20 8123 2220
info@marketpublishers.com

Metal

Monoclonal antibodies

Nanoparticle

Oncolytic viruses

Peptide

Plasmid

Protein

Small molecule

Ligand

Bacteria and others.

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Lymphangioleiomyomatosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I and preclinical stage. It also analyses Lymphangioleiomyomatosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lymphangioleiomyomatosis drugs.

Report Highlights

+44 20 8123 2220
info@marketpublishers.com

The companies and academics are working to assess challenges and seek opportunities that could influence Lymphangioleiomyomatosis R&D. The therapies under development are focused on novel approaches to treat/improve Lymphangioleiomyomatosis.

Lymphangioleiomyomatosis Report Insights

Lymphangioleiomyomatosis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Lymphangioleiomyomatosis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Lymphangioleiomyomatosis drugs?

How many Lymphangioleiomyomatosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for

+44 20 8123 2220
info@marketpublishers.com

the treatment of Lymphangioleiomyomatosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lymphangioleiomyomatosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Lymphangioleiomyomatosis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AI Therapeutics

AstraZeneca

Key Products

Rapamycin

Saracatinib

+44 20 8123 2220
info@marketpublishers.com

Contents

Introduction
Executive Summary
Lymphangioleiomyomatosis: Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Lymphangioleiomyomatosis – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
  Lymphangioleiomyomatosis companies' collaborations, Licensing, Acquisition -Deal Value Trends
Lymphangioleiomyomatosis Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products
  Comparative Analysis
Rapamycin- AI Therapeutics
  Product Description
  Research and Development
  Product Development Activities
Saracatinib: AstraZeneca
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products
  Comparative Analysis

+44 20 8123 2220
info@marketpublishers.com

Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Non Muscle Invasive Bladder Cancer Key Companies
Non Muscle Invasive Bladder Cancer Key Products
Non Muscle Invasive Bladder Cancer- Unmet Needs
Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
Non Muscle Invasive Bladder Cancer Analyst Views
Non Muscle Invasive Bladder Cancer Key Companies
Appendix

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1 Total Products for Non Muscle Invasive Bladder Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Non Muscle Invasive Bladder Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Lymphangioleiomyomatosis (LAM) - Pipeline Insight, 2020

Product link: https://marketpublishers.com/r/L6E60B52FBB3EN.html

Price: US$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/L6E60B52FBB3EN.html